5-[(R)-(1,3-dimethylazetidin-3-yl)-hydroxy-(4-propan-2-ylphenyl)methyl]-N-(oxan-4-yl)pyridine-3-carboxamide
C26H35N3O3 — CID 157026054
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[(R)-(1,3-dimethylazetidin-3-yl)-hydroxy-(4-propan-2-ylphenyl)methyl]-N-(oxan-4-yl)pyridine-3-carboxamide
5-[(R)-(1,3-dimethylazetidin-3-yl)-hydroxy-(4-propan-2-ylphenyl)methyl]-N-(oxan-4-yl)pyridine-3-carboxamide (PubChem CID 157026054) has the molecular formula C26H35N3O3 and a molecular weight of 437.58 g/mol. Its IUPAC name is 5-[(R)-(1,3-dimethylazetidin-3-yl)-hydroxy-(4-propan-2-ylphenyl)methyl]-N-(oxan-4-yl)pyridine-3-carboxamide.
Molecular Properties
| Compound Name | 5-[(R)-(1,3-dimethylazetidin-3-yl)-hydroxy-(4-propan-2-ylphenyl)methyl]-N-(oxan-4-yl)pyridine-3-carboxamide |
|---|---|
| PubChem CID | 157026054 |
| Molecular Formula | C26H35N3O3 |
| Molecular Weight | 437.58 g/mol |
| Exact Mass | 437.27 |
| IUPAC Name | 5-[(R)-(1,3-dimethylazetidin-3-yl)-hydroxy-(4-propan-2-ylphenyl)methyl]-N-(oxan-4-yl)pyridine-3-carboxamide |
| SMILES | CC(C)c1ccc([C@](O)(c2cncc(C(=O)NC3CCOCC3)c2)C2(C)CN(C)C2)cc1 |
| InChI | InChI=1S/C26H35N3O3/c1-18(2)19-5-7-21(8-6-19)26(31,25(3)16-29(4)17-25)22-13-20(14-27-15-22)24(30)28-23-9-11-32-12-10-23/h5-8,13-15,18,23,31H,9-12,16-17H2,1-4H3,(H,28,30)/t26-/m0/s1 |
| InChIKey | FXAQGDBBAPMPCL-SANMLTNESA-N |
| XLogP | 3.30 |
| TPSA | 74.69 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 437.58 |
| LogP ≤ 5 | 3.30 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 157026054 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.